ABSTRACT
This study evaluated the anti-oxidant and anti-diabetic potential of Caralluma fimbriata (CF) in 28-days rat modelling trial. Diabetes is a chronic disorder characterized by elevated blood glucose levels and insulin resistance and cause microvascular and macrovascular issues. Caralluma fimbriata was evaluated for its nutritional composition along with anti-oxidant potential of CF powder (CFP) and CF extract (CFE) using total phenolic contents (TPC), 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing antioxidant power (FRAP) assays. Furthermore, anti-diabetic potential was computed by dividing rats into four groups of 5 individuals each. Rats of Group I was non-diabetic and no supplementation was given while rats of group II were diabetic and no supplementation was given. While group III and group IV rats were diabetic and received CFP and CFE supplementation respectively. CF powder's TPC, and DPPH and FRAP activity were observed maximum at 44.17 ± 0.006 (µgFe/g) in water, 68.75 ± 0.49 (µgFe/g) in acetone and 800.81 ± 0.99 (µgFe/g) in hexane. Supplementation of CFP and CFE reduced blood glucose effectively i.e. (125.00 ± 4.04 and 121.00 ± 4.49 mg/dL, respectively). Moreover, the consumption of C. fimbriata can be helpful in the management of diabetes mellitus due to its glucose lowering potential, anorexic effects, anti-oxidant potential and α-amylase inhibition.
ABSTRACT
Herein, a new series of azo ligands HL-1 (5-(2-chloro-6-(phenylcarbonyl)phenyl)diazenyl)-6-hydroxydihydropyrimidines-2,4dione), HL-2 (5-(2-chloro-6-(phenylcarbonyl)phenyl)diazenyl)-6-hydroxy-2-thioxottetrahydropyrimidin-4one), HL-3 (5-(2,4-dichloro-6-(phenylcarbonyl)phenyl) diazenyl)-6-hydroxydihydropyrimidines-2,4dione), HL-4 (5-(2,4-dichloro-6-(phenylcarbonyl) phenyl)diazenyl)-6-hydroxy-2-thioxotetrahydropyrimidin-4one) and their metal complexes with Cu(II) & Ni(II) were synthesized successfully having excellent yield, in reproducible conditions and for structure elucidation different advance spectroscopic techniques (FTIR, 1H NMR, 13C NMR and Mass Spectrometry) were applied. In FTIR analysis, the absence of peak at 3450-3550 cm -1 due to -NH2 and presence of a new peak of N=N at 1390-1520 cm-1 confirmed synthesis of the ligands. The 1H NMR spectra of azo ligands showed singlet peak at 11.5-13.5 ppm (Ar-OH) for hydroxyl group and -NH2 signals disappearance of anilines at 4-5 ppm also gives strong indication for the synthesis of azo compounds. On complexation two most important peaks (M-O, M-N) appeared in all the metal chelates in the range of 400-600 cm-1 which were not present in any of the ligands, confirmed the formation of complexes. Molecular ion peaks in mass spectra at 273, 388, 407 and 423 m/z value for ligands as well as for complexes at 803, 835, 871 and 904 m/z also give strong indication that proposed ligands and their metal complexes are produced successfully. Biological screening of the synthesized compounds were also carried out against different bacterial strains (E.coli, S.typhi, and B.subtilis), antifungal (C.albicans, A.niger, and C.glabrata) strains and antioxidant activity. From results it was observed that HL-4 and Cu complexes exhibited maximum inhibition against all bacterial and fungal strains as compared to other ligands and standard drug.
ABSTRACT
Molecularly imprinted biodegradable polymers are receiving considerable attention in drug delivery due to their ability of targeted recognition and biocompatibility. This study reports the synthesis of a novel fluorescence-active magnetic molecularly imprinted drug carrier (MIDC) using a glucose-based biodegradable cross-linking agent for the delivery of anticancer drug docetaxel. The magnetic molecularly imprinted polymer (MMIP) was characterized through scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction spectroscopy, and vibrating sample magnetometry (VSM). The MMIP presented a magnetization value of 0.0059 emu g-1 and binding capacity of 72 mg g-1 with docetaxel. In vitro and in vivo studies were performed to observe the effectiveness of the MIDC for drug delivery. The cell viability assay suggested that the MMIP did not present toxic effects on healthy cells. The magnetic property of the MMIP allowed quick identification of the drug carrier at the target site by applying the external magnetic field to mice (after 20 min of loading) and taking X-ray images. The novel MMIP-based drug carrier could thus deliver the drug at the target site without affecting the healthy cells.
